These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206 [TBL] [Abstract][Full Text] [Related]
12. Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. Morenas-Rodríguez E; Cervera-Carles L; Vilaplana E; Alcolea D; Carmona-Iragui M; Dols-Icardo O; Ribosa-Nogué R; Muñoz-Llahuna L; Sala I; Belén Sánchez-Saudinós M; Blesa R; Clarimón J; Fortea J; Lleó A J Alzheimers Dis; 2016; 50(2):539-46. PubMed ID: 26682689 [TBL] [Abstract][Full Text] [Related]
13. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia. Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286 [TBL] [Abstract][Full Text] [Related]
14. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study. Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276 [TBL] [Abstract][Full Text] [Related]
15. The use of proteomics in biomarker discovery in neurodegenerative diseases. Davidsson P; Sjögren M Dis Markers; 2005; 21(2):81-92. PubMed ID: 15920295 [TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Portelius E; Olsson B; Höglund K; Cullen NC; Kvartsberg H; Andreasson U; Zetterberg H; Sandelius Å; Shaw LM; Lee VMY; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk DA; McCluskey L; Elman L; McBride J; Toledo JB; Trojanowski JQ; Blennow K Acta Neuropathol; 2018 Sep; 136(3):363-376. PubMed ID: 29700597 [TBL] [Abstract][Full Text] [Related]
17. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248 [TBL] [Abstract][Full Text] [Related]